The DOI matches its Crossref record; 411 of the 411 references it cites were found in a registry or an index.
Rescuing the Last-Line Polymyxins: Achievements and Challenges
Open accessAbstract
, and Enterobacterales. Polymyxins were first discovered in the late 1940s but were abandoned soon after their approval in the late 1950s as a result of toxicities (e.g., nephrotoxicity) and the availability of "safer" antibiotics approved at that time. Therefore, knowledge on polymyxins had been scarce until recently, when enormous efforts have been made by several research teams around the world to elucidate the chemical, microbiological, pharmacokinetic/pharmacodynamic, and toxicological properties of polymyxins. One of the major achievements is the development of the first scientifically based dosage regimens for colistin that are crucial to ensure its safe and effective use in patients. Although the guideline has not been developed for polymyxin B, a large clinical trial is currently being conducted to optimize its clinical use. Importantly, several novel, safer polymyxin-like lipopeptides are developed to overcome the nephrotoxicity, poor efficacy against pulmonary infections, and narrow therapeutic windows of the currently used polymyxin B and colistin. This review discusses the latest achievements on polymyxins and highlights the major challenges ahead in optimizing their clinical use and discovering new-generation polymyxins. To save lives from the deadly infections caused by Gram negative "superbugs," every effort must be made to improve the clinical utility of the last-line polymyxins. SIGNIFICANCE STATEMENT: Antimicrobial resistance poses a significant threat to global health. The increasing prevalence of multidrug-resistant (MDR) bacterial infections has been highlighted by leading global health organizations and authorities. Polymyxins are a last-line defense against difficult-to-treat MDR Gram negative pathogens. Unfortunately, the pharmacological information on polymyxins was very limited until recently. This review provides a comprehensive overview on the major achievements and challenges in polymyxin pharmacology and clinical use and how the recent findings have been employed to improve clinical practice worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–411 of 411
Zhao, M., Wu, X., Fan, Y., Zhang, Y., Guo, B., Yu, J., Cao, G.-Y., Chen, Y., Wu, J., Shi, Y., et al. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.12.025 · Cited by 19
Self-citationHan, M., Liu, X., Velkov, T., Lin, Y., Zhu, Y., Li, M., Yu, H. H., Zhou, Z., Creek, D. J., Zhang, J., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02776 · Cited by 19
Self-citationGuo, W., Guo, S.-C., Li, M., Li, L.-H., & Qu, Y. (2018) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-018-0313-5 · Cited by 17
CHEMICAL STUDIES ON POLYMYXIN B 1
Regna, P. P., Solomons, I. A., Forscher, B. K., & Timreck, A. E. (1949) · Journal of Clinical Investigation · doi:10.1172/jci102133 · Cited by 15
Li, J., Coulthard, K. P., & Nation, R. L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16373-0_10 · Cited by 14
Self-citationRelationship between structure and histamine releasing action of polymyxin B and its analogues
Voitenko, V. G., Bayramashvili, D. I., Zebrev, A. I., & Zinchenko, A. A. (1990) · Inflammation Research · doi:10.1007/bf01969025 · Cited by 13
Tang, H.-J., Ku, Y.-H., Lee, M.-F., Chuang, Y.-C., & Yu, W. (2015) · BioMed Research International · doi:10.1155/2015/568079 · Cited by 13
Córdoba, J. P., Coronado-Álvarez, N. M., Parra, D., & Parra-Ruiz, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00493-15 · Cited by 12
Guzel, C. B., & Gerçeker, A. A. (2012) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.93020 · Cited by 8
Haeili, M., Kafshdouz, M., Pishnian, Z., Feizabadi, M. M., & Martı́nez-Martı́nez, L. (2018) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000879 · Cited by 6
Macedo, S., Gonçalves, I., Bispo, G., de Almeida, L. R., & Brito, L. B. (2011) · Critical Care · doi:10.1186/cc9655 · Cited by 2
Cited by
Tolerance and resistance of microbial biofilms
Ciofu, O., Moser, C., Jensen, P. Ø., & Høiby, N. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00682-4 · Cited by 1,124
Klebsiella pneumoniae carbapenemase variants: the new threat to global public health
Ding, L., Shen, S., Chen, J., Tian, Z., Shi, Q., Han, R., Guo, Y., & Hu, F. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-23 · Cited by 222
Lipopeptide antibiotics disrupt interactions of undecaprenyl phosphate with UptA
Oluwole, A. O., Kalmankar, N. V., Guida, M., Bennett, J. L., Poce, G., Bolla, J. R., & Robinson, C. V. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2408315121 · Cited by 13
Metadata
- Authors
- Nang, S. C., Azad, M. A. K., Velkov, T., Zhou, Q. (., & Li, J.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 73
- Issue
- 2
- Pages
- 679-728
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W3131147063
- Cited by
- 421
- References
- 411
- FWCI
- 17.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.